The role of the efflux transporter, P‐glycoprotein, at the blood–brain barrier in drug discovery
Biopharmaceutics & Drug Disposition · 2023-02 · 44 (1) · 113-126
DOI: 10.1002/bdd.2331 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biopharmaceutics & Drug Disposition, online erschienen am 17.10.2022. Verfasst von Benoit Cox und 2 weiteren Autor:innen. Beteiligte Einrichtung: DMPK, Development Sciences, UCB Biopharma, Braine-l'Alleud, Belgium. Hauptthemen laut MEDLINE: Blood-Brain Barrier, ATP Binding Cassette Transporter, Subfamily B, Member 1. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 120 Literaturangaben.
Abstract (Originalsprache)
The blood–brain barrier (BBB) expresses a high abundance of transporters, particularly P‐glycoprotein (P‐gp), that regulate endogenous and exogenous molecule uptake and removal of waste. This review discusses key drug metabolism and pharmacokinetic considerations for the efflux transporter P‐gp at the BBB in drug discovery and development. We highlight the differences in P‐gp expression and protein levels across species but the limited observations of species‐specific substrates. Given the impact of age and disease on BBB biology, we summarise the modulation of P‐gp for several neurological disorders and ageing and exemplify several disease‐specific hurdles or opportunities for drug exposure in the brain. Furthermore, the review includes observations of CNS‐related drug‐drug interactions due to the inhibition or induction of P‐gp at the BBB in animal studies and humans and the need for continued evaluation especially for compounds with a narrow therapeutic window. This review focusses primarily on small molecules but also considers the impact of new chemical entities, particularly beyond Ro5 molecules and their potential to be recognised as P‐gp substrates as well as advanced drug delivery systems which offer an alternative approach to achieve and sustain central nervous system exposure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- DMPK, Development Sciences, UCB Biopharma, Braine-l'Alleud, Belgium.
- DMPK, Janssen Pharmaceutical Companies of Johnson & Johnson, Janssen Research & Development, Beerse, Belgium.
- DMPK, Development Sciences, UCB Biopharma, Slough, UK.
ORCID-Profile: Benoit Cox, Beth Williamson
Zitieren
APA
Cox, B., Nicolaï, J., & Williamson, B. (2023). The role of the efflux transporter, P‐glycoprotein, at the blood–brain barrier in drug discovery. Biopharmaceutics & Drug Disposition, 44(1), 113-126. https://doi.org/10.1002/bdd.2331
Vancouver
Cox B, Nicolaï J, Williamson B. The role of the efflux transporter, P‐glycoprotein, at the blood–brain barrier in drug discovery. Biopharmaceutics & Drug Disposition. 2023;44(1):113-126. doi:10.1002/bdd.2331
BibTeX
@article{Cox2023,
author = {Cox, Benoit and Nicolaï, Johan and Williamson, Beth},
title = {The role of the efflux transporter, P‐glycoprotein, at the blood–brain barrier in drug discovery},
journal = {Biopharmaceutics & Drug Disposition},
year = {2023},
volume = {44},
number = {1},
pages = {113--126},
doi = {10.1002/bdd.2331}
}
EUVIMED